Searched for
BIOCON FINANCIAL PERFORMANCE
Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...- Biocon reports 63% YoY fall in Q4 profit, final dividend of Rs. 0.50 recommendedBiocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to exceptional charges im...
- Biocon Q4 Results: Net profit down 57% at Rs 198.6 croreBiocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolida...
- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- Biocon Q2 Results: Profit soars 428% YoY to Rs 85 crore on strong biosimilar and generics growthBiocon Group reported a strong Q2 FY26 with a 20% year-on-year increase in operating revenue to Rs 4,296 crore, driven by biosimilars and g...
- Biocon plans ₹4,500-cr QIP to raise stake in Biologics unit: Kiran ShawBiocon is planning a ₹4,500 crore fundraise to increase promoter stake in Biocon Biologics and convert structured venture debt into equity,...
- Biocon Q4 results: Net profit surges 153% at Rs 344 croreBiocon reported a significant surge in Q4 net profit, up 153% to Rs 344 crore, with revenue growing 12% to Rs 4,454 crore. The company's bi...
- Biocon shares fall 6% after Q2 net profit dives 84%. What should investors do?Axis Securities and JM Financial both maintain 'Buy' ratings on Biocon, with target prices of Rs 370 and Rs 380, respectively. Biocon has a...
- Biocon denies plans to sell $1.5 billion generic API businessBiocon API business: Biocon has refuted claims of considering the sale of its generic active pharmaceutical ingredient (API) business, valu...
- On track to integrate major part of Viatris'' acquired biosimilars biz this fiscal: Kiran Mazumdar-ShawBiocon Biologics is set to integrate a major portion of the biosimilars business acquired from Viatris in the current fiscal year, accordin...
- Biocon Q4 Results: Net profit jumps 31% on strong biosimilar business growthIndian biopharmaceutical company Biocon posted a 31% year-on-year rise in Q4 FY23 net profit, at INR313 crore ($41.9m), driven by successfu...
- Biocon net profit rises 71 pc to Rs 144 crore in June quarterTotal revenue rose to Rs 2,217 crore in the first quarter as compared with Rs 1,808 crore in the year-ago period, Biocon said in a regulato...
- Biocon Q4 Results: Profit declines 4% to Rs 283 crConsolidated revenue from operations in the fourth quarter stood at Rs 2,408.8 crore as against Rs 1,842.1 crore in the year-ago period, it...
- Biocon Biologics set to reap biosimilar insulin glargine opportunity in USDrugmaker Biocon is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and pr...
- Biocon Q4 results: Profit dips 42% on one-time Covid-19 impactFor the financial year 2019-20, the biopharma company posted a 15% growth in revenue at Rs 6,529 crore.
- Biocon elevates M B Chinappa as CFO of biosimilar subsidiaryM B Chinappa, who is going to play an important role in Biocon Biologics’ journey towards becoming a global leader in biologics, has been t...
- Biocon posts marginal 2 per cent growth in net profit for Q4FY18Biocon posted a net profit of Rs 130 crore for the quarter ended March 31, 2018. The company had recorded a net profit of Rs 127 crore for ...
- Biocon Q2 net profit jumps 3-fold at Rs 306 croreThe consolidated revenue of Biocon was up by 11.38 per cent at Rs 861 crore during the quarter compared to Rs 773 crore in the year-ago per...
- Biocon Q1 Net up 9% to Rs 103 crore"We are working towards diversifying our regional dependencies to diminish the impact of such externalities," Biocon CMD Kiran Mazumdar-Sha...
- Biocon PAT at Rs 39 cr in Q1Biocon Limited on Wednesday maintained a profit after tax (PAT) at Rs 39 crore for the quarter ended June 30 in comparision to the same qua...
Load More
